Active, not recruitingPhase 3NCT03522246
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- pharmaand GmbH
- Intervention
- Rucaparib(drug)
- Enrollment
- 1097 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2018 – 2030
Study locations (30)
- Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
- Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
- The University of Arizona Cancer Center, Tucson, Arizona, United States
- John Muir Clinical Research Center, Concord, California, United States
- UCLA Women's Health Clinical Research Unit, Los Angeles, California, United States
- Kaiser Permanente Northern California, San Francisco, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Rocky Mountain Cancer Centers, Lakewood, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Florida Gynecologic Oncology, Fort Myers, Florida, United States
- MD Anderson Cancer Center-Baptist, Jacksonville, Florida, United States
- Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States
- Florida Hospital, Orlando, Florida, United States
- Northside Hospital, Atlanta, Georgia, United States
- Augusta University, Augusta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb · Gynecologic Oncology Group · European Network of Gynaecological Oncological Trial Groups (ENGOT) · Foundation Medicine
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03522246 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd